Join Jaclyn Assarian, an Outreach and Recruitment Specialist with the Fulbright U.S. Scholar Program, as she details the support offered to faculty and professionals to conduct research, teach, and carry out professional projects in over 135 countries around the world.
Join Professor Sarbajit Banerjee of Texas A&M University and Senior Editor of ACS Omega, as he discusses his thoughts about how to evaluate your fit with a specific program or research group, resources for professional development, and career pathways in the chemical sciences.
Join Program Manager and Assistant Director Nancy Jensen of the Office of Research Grants at ACS as she provides practical tips for identifying funding sources, suggests effective approaches for presenting research plans, and identifies some common pitfalls in preparing proposals.
Join Jordan Harshman of Auburn University and Anne Kondo of Indiana University of Pennsylvania for a discussion about how undergraduate and graduate students can be better prepared for collaborative work.
Join Matt Grandbois of DuPont Electronics & Industrial as he guides you through how to make a development plan that strings together functional experiences into a successful career as a professional chemist.
Join Stephen Buckley of Novo Nordisk for an in-depth overview of the integrated approach employed in the discovery and development of oral semaglutide, a GLP-1 analogue coformulated with the absorption enhancer sodium N-[8-(2-hydroxybenzoyl) aminocaprylate] (SNAC) in a tablet.
Join attorney Robert Migliorini of Exxon Mobil Corporation as he shares how to protect your technology and IP interests by making sure the appropriate agreements are in place at the start that cover essential aspects like confidential and proprietary information, trade secrets, inventions and patent applications.
KRAS is one of the most frequently mutated oncogenes in human cancer. Despite more than three decades of research, indirect approaches targeting KRAS-mutant cancers have largely failed to show clinical benefit, and direct approaches have been stymied by the apparently ‘undruggable’ nature of KRAS.